Patient-Derived Xenograft (PDX) Model Development Services
Alfa Cytology specializes in comprehensive patient-derived xenograft (PDX) model development services. We are committed to creating robust, reliable PDX models, helping researchers around the world streamline the drug development process.
Introduction to Patient-Derived Xenograft (PDX) Model
Patient-derived tumor xenograft models (PDX) are tumor models created by transplanting fresh tumor tissue from a patient directly into an immunodeficient mouse, which allows tumors to grow in living organisms while maintaining the original histological and genetic characteristics of the patient's tumor. The PDX model does not require artificial culture and maintains the heterogeneity of the tumor, resulting in a more complete biology and the ability to accurately replicate the human tumor microenvironment, which is the best tumor animal model at this stage.
Fig.1 Protocols of humanized patient-derived tumor xenografts (PDX) model construction. (Zhang, W., & Zheng, X., 2023)
Applications and Research Trends of PDX Model
Patient-derived tumor xenografts (PDX), as a classical in vivo experimental method, are widely used in all stages of drug development, from target validation and lead compound optimization to preclinical efficacy and safety studies. Recent advances in PDX model development include the creation of humanized PDX models, where mice are engrafted with human hematopoietic stem cells to reconstitute a human immune system. This innovation has expanded the utility of PDX models in immuno-oncology.
Our Services
Alfa Cytology offers a wide range of patient-derived xenograft (PDX) models for a variety of cancer types, designed to support preclinical and translational research in cutting-edge cancer therapies. We have more than 3,000 models in place, and these models are continuously updated with the latest research hotspots.
Workflow of Patient-Derived Xenograft (PDX) Model Development
Cryopreservation
Cell Authentication
Efficacy Evaluation
Patient-Derived Xenograft (PDX) Models Available
Breast Cancer
Cervical Cancer
Endometrial Cancer
Esophageal Cancer
Melanoma
Pancreatic Cancer
Pharyngeal Cancer
Advantages of Our PDX Models
With our rigorous standardized procedures, we custom develop PDX models with a high degree of accuracy and relevance to aid in the study of human cancer biology, increasing the translational potential of research results.
Retention of Tumor Heterogeneity
Our PDX models retain the original patient's tumor's histological and genetic diversity, ensuring accurate representation of intra-tumoral heterogeneity.
Customization and Scalability
PDX models are customizable and scalable to fit specific research needs, enabling tailored experiments and high-throughput drug screening.
Human-like Tumor Microenvironment
Our models preserve the human tumor microenvironment, including stromal cells and extracellular matrix, facilitating the study of tumor-stroma interactions.
Compatibility with Advanced Research Techniques
These models are compatible with next-generation sequencing, immunohistochemistry, and in vivo imaging, allowing for comprehensive molecular and cellular analyses.
With extensive experience in various cancer models and expertise in a wide range of cancer modeling, Alfa Cytology is the ideal partner to support your oncology therapeutic research. We provide customers with stock model products, model customization, and joint R&D services to provide you with the best tumor models and look forward to meeting your precise needs. Please let us know your project requirements and we will provide you with a comprehensive service from solution to report. For further inquiries and custom model development, please feel free to
contact us.
References
- Yu, N., et al. Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer. Journal of experimental & clinical cancer research. 2023, 42(1): 37.
- Zhang, W., & Zheng, X. (2023). Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy. Frontiers in Oncology, 13, 1122322.
For research use only.
Related Services
